Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Molecular Testing for CCA

October 21st 2019

Second-Line Therapy for CCA

October 21st 2019

Frontline Therapy for CCA

October 21st 2019

Radiation Therapy for CCA

October 21st 2019

Adjuvant Chemotherapy for CCA

October 21st 2019

Prevalence of CCA

October 21st 2019

Tumor Markers in CCA

October 21st 2019

Heterogeneity of CCA

October 21st 2019

Diagnosing CCA

October 21st 2019

Dr. Richards on Genetic Testing in Metastatic Pancreatic Cancer

October 21st 2019

Donald A. Richards, MD, PhD, discusses the use of genetic testing in patients with metastatic pancreatic cancer.

Advances in Small Bowel Cancer Generate New NCCN Guidelines

October 20th 2019

A new set of recommendations for the treatment of small bowel adenocarcinoma, a relatively rare type cancer of the gastrointestinal tract, have been created by the National Comprehensive Cancer Network. The guidelines are the first in the United States and second in the world to recommend treatments specific to the malignancy, which is often diagnosed at advanced stages.

Dr. Weinberg on Targeted Therapies for Molecular Subsets of mCRC

October 17th 2019

Benjamin Weinberg, MD, discusses treatment strategies for patients with different molecular subtypes of metastatic colorectal cancer.

Dr. Lee on Trial Data Evaluating the Atezolizumab/Bevacizumab in Unresectable HCC

October 17th 2019

Michael S. Lee, MD, discusses trial data evaluating the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in unresectable hepatocellular carcinoma.

Chemotherapy Triplet Elicits Encouraging Activity in Pancreatic Adenocarcinoma

October 17th 2019

The addition of cisplatin to gemcitabine and nab-paclitaxel resulted in encouraging activity in patients with previously untreated advanced pancreatic cancer, despite not having demonstrated the prespecified number of complete responses to meet the primary endpoint of a phase Ib/II clinical trial (NCT01893801), according to findings published in JAMA Oncology.

Pegilodecakin Falls Short in Phase III Pancreatic Cancer Trial

October 16th 2019

Combining the pegylated IL-10 pegilodecakin with FOLFOX (folinic acid, 5-FU, oxaliplatin) chemotherapy did not improve overall survival as a second-line therapy for patients with metastatic pancreatic cancer.

Dr. Bekaii-Saab on the Addition of Atezolizumab to Capecitabine/Bevacizumab in MSS mCRC

October 15th 2019

Tanios S. Bekaii-Saab, MD, FACP, discusses the results of the phase II BACCI trial evaluating the addition of atezolizumab to capecitabine plus bevacizumab versus capecitabine/bevacizumab plus placebo in patients with microsatellite stable metastatic colorectal cancer.

Dr. Shroff on Genomic Landscape of Cholangiocarcinoma

October 15th 2019

Rachna T. Shroff, MD, MS, discusses actionable targets in intrahepatic and extrahepatic cholangiocarcinoma.

TAS-102 Effective in Gastric/GEJ Cancer, Regardless of Prior Gastrectomy

October 15th 2019

Patients with metastatic gastric or gastroesophageal junction cancer had improved overall survival with TAS-102, irrespective of prior gastrectomy.

Dr. Bekaii-Saab on Safety Profile of Tucatinib/Trastuzumab in HER2-Amplified mCRC

October 11th 2019

Tanios S. Bekaii-Saab, MD, discusses the safety profile of the combination of tucatinib and trastuzumab in patients with HER2-amplified metastatic colorectal cancer.

Potential Molecular Markers in Liver Cancer

October 11th 2019

Anuradha S. Budhu, PhD, discusses using molecular features as predictive markers in liver cancer.